Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-12-21 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Ultomiris accepted for FDA Priority Review for gMG
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 3208W' and is dated '21 December 2021'. It announces regulatory news regarding an FDA Priority Review acceptance for a supplemental Biologics License Application (sBLA) for Ultomiris. The text concludes with standard disclaimers and contact information related to RNS (the news service of the London Stock Exchange) and the FCA. This format is characteristic of a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like a 10-K, ER, or IR. Since it is a regulatory announcement that doesn't fit the specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback is RNS.
2021-12-21 English
TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the approval of Tezspire in the US for severe asthma, including clinical trial results, regulatory review status, and collaboration details. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. This document is not an annual report, earnings release, or any other specific financial report but rather a regulatory announcement of significant corporate news. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains substantive information rather than just an announcement of a report publication, so it is not an RPA. There is no indication of it being a certification or attestation, so it is not a certification filing. Hence, the most appropriate classification is Regulatory Filings (RNS).
2021-12-20 English
SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the recommendation for EU approval of the drug Saphnelo for systemic lupus erythematosus (SLE), including clinical trial results, regulatory status, and company background. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about the company's product development and regulatory progress. The document length is over 14,000 characters and contains substantive content, not just an announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-20 English
Tezspire approved in the US for severe asthma
Regulatory Filings Classification · 100% confidence The document is a press release issued on December 20, 2021, identified by the RNS Number (Regulatory News Service). The content announces the US approval of Tezspire (tezepelumab) for severe asthma and details the clinical trial results (NAVIGATOR trial) supporting this approval. This type of announcement, which communicates key business and regulatory achievements (like drug approval) via a formal news service, is characteristic of a general regulatory announcement or press release. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dedicated earnings release (ER), and it is a formal regulatory notification, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such announcements not covered by more specific codes.
2021-12-20 English
Saphnelo recommended for EU approval for SLE
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 1194W' and concludes with standard RNS closing statements, indicating it is a regulatory announcement distributed via the London Stock Exchange's RNS service. The content announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the marketing authorisation of a drug (Saphnelo) in the EU. This type of announcement, which is a material update but not a full financial report (like 10-K or IR) or a specific insider trade/dividend notice, fits best under the general regulatory announcement category. Since it is a specific, time-sensitive regulatory update distributed via RNS, 'RNS' is the most appropriate code, although 'LTR' (Legal Proceedings Report) or 'ER' (Earnings Release) are clearly incorrect. Given the context of a general regulatory news service distribution, RNS is the best fit among the provided options for a non-standard, material announcement.
2021-12-20 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting a transaction by a person discharging managerial responsibilities (PDMR), specifically a Non-Executive Director purchasing shares. The content focuses on insider shareholding disclosure, detailing the purchase of American Depositary Shares by a director. It does not contain financial statements, earnings data, or management discussion. The document is about a director's personal share transaction, which fits the definition of Director's Dealing filings. The document length is 4216 characters, which is consistent with a detailed insider transaction report rather than a full financial report or announcement. Therefore, the appropriate classification is Director's Dealing (DIRS).
2021-12-15 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.